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editorial
Biomarkers and efficacy: are we nearly
there yet?
At the moment, several studies provide strong evidence that the
genotyping of tumors is mandatory in patients with metastatic
colorectal cancer (CRC) before treatment with antiepidermal
growth factor receptor (anti-EGFR) monoclonal antibodies.
In this issue of Annals of Oncology, the update of the
Oxaliplatin and Cetuximab in First-Line Treatment of
Metastatic Colorectal Cancer (OPUS) phase II study assesses
the efficacy and safety of cetuximab combined with first-line
oxaliplatin-based chemotherapy for metastatic colorectal
cancer patients [1]. The influence of KRAS and BRAF mutation
status on primary and secondary end points of the study was
evaluated.
The preliminary data of the study have already been published
and confirm that KRAS mutation status is a powerful predictive
factor in relation to the efficacy of cetuximab treatment [2].
Along with efficacy data in terms of response rate, overall
survival (OS) and progression-free survival (PFS) according to
KRAS and BRAF mutation status, the present analysis also
reports the incidence of toxic effects in the intention to treat
(ITT) and biomarker populations.
It should be remarked that the potential bias initially
associated with the retrospective evaluation of the mutational
status of KRAS in the OPUS study seems irrelevant today, since
the difference between the ITT population and the population
assessable for KRAS, that are made up of 337 versus 315 (93%)
patients respectively, is negligible.
Although all patients with a KRAS mutation are presently
excluded from treatment with anti-EGFR antibodies, the
quantitative PCR-based assays used in the OPUS study could
identify only 7 of 12 known KRAS gene mutations in exon 2
(codons 12 and 13) and none in exon 3 (codons 59, 61 and 63).
Moreover, some reports suggest that specific KRAS
mutations have a prognostic role but not even a predictive role
with regard to anti-EGFR therapies. KRAS mutations at codon
13 are associated with a worse prognosis in sporadic CRC, as
reported for the first time in a prospective study carried out by
our group [3] and recently confirmed in a Japanese series [4].
Furthermore, an individual patient data pooled analysis
indicated that some KRAS codon 13-mutated patients may be
sensitive to cetuximab treatment when compared with patients
with other KRAS-mutated tumors, and that all codon 13
responders carry the p.G13D mutation [5].
The choice for the most appropriate method in KRAS
mutation analysis remains a complex challenge, as it is still not
known what level of test sensitivity is required in order to
provide useful and predictive information in clinical practice.
Direct dideoxy DNA sequencing and the PCR-based assays
would seem to be the most reliable techniques, but the
detection limit of these two methods is 20% and 10% mutant
alleles, respectively [6]. Some researchers attempted to find
more sensitive methods, such as pyrosequencing, so as to
obtain the same results with fewer cells from the specimens. In
a brief report by Santini et al. [7], 3 of 29 KRAS wild-type (by
real-time PCR) patients who received an anti-EGFR therapy
proved to be mutant by pyrosequencing. All of these mutated
patients showed partial response according to RECIST criteria
as best response during cetuximab-based chemotherapy, thus
suggesting that a small percentage of KRAS-mutated tumor
cells does not impair cetuximab activity.
It has been hypothesized that there is a possible switch of
a CRC from wild type to mutant KRAS form with the result
that the mutation status of the primary tumor might not be
adequate to predict the response of metastases to anti-EGFR
treatment. In fact, several reports have now demonstrated
a high level of concordance between KRAS mutation in the
primary tumor and liver metastasis in CRC so that both
primary tumors and liver metastases can be used for KRAS
mutation analysis. More specifically, our group, in a series of 99
patients found a high concordance between primary and
related metastases, mostly involving the liver, in terms of KRAS
mutational status [8]. This report has recently been confirmed
in a large and homogenous Dutch study, which found
a discordance between primary tumors and corresponding liver
metastases in only 11 of 305 cases (3.6%) [9].
Overall, KRAS mutation seems to be responsible in 35%–
45% cases for resistance to anti-EGFR antibodies. Another
group of patients, representing 5%–10% of the total number of
CRC patients, carry the BRAF mutation, which is mutually
exclusive with KRAS mutations. Although is difficult to reach
a definite conclusion concerning the possible predictive or
prognostic utility of BRAF, because of the limited sample size, it
nevertheless seems that BRAF mutations may play a strong
negative prognostic role and only a slight role in predicting
resistance to anti-EGFR antibodies.
BRAF mutational status has been evaluated in patients from
the Cetuximab Combined with Irinotecan in First-Line Therapy
for Metastatic Colorectal Cancer and OPUS studies and no
significant efficacy difference between the treatment arms
(chemotherapy with and without Cetuximab) in the wild-type
KRAS/mutated BRAF group has been found [10]. Nevertheless,
these patients seem to benefit from the addition of Cetuximab,
with an increase of OS and a doubling of PFS rates.
Furthermore, there is clearly a worse outcome in mutated BRAF
in comparison with wild-type BRAF patients independently of
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a possible negative prognostic role of BRAF mutations. In the
CAIRO-2 study, a similar pattern was observed in a large series
of metastatic colorectal cancer (mCRC) patients treated with
chemotherapy and Bevacizumab either with or without
Cetuximab. It was seen that the BRAF mutation was associated
with a worse outcome, both in terms of PFS and of OS,
independently of the addition of Cetuximab to the treatment
[11]. To date, therefore, the negative predictive value of
mutations of BRAF is suggested only by single-arm retrospective
analyses on tissue samples from patients treated with anti-EGFR
antibodies [12–14], while the significant negative prognostic
value seems now to have been established [4, 15].
The absence, however, of KRAS/BRAF mutations does not
guarantee an increased likelihood of response to these drugs,
since wild-type KRAS/BRAF status is not sufficient to confer
sensitivity to anti-EGFR monoclonal antibodies. As a result, the
investigation of other biomarkers such as EGFR copy number
and messenger RNA expression levels of EGFR ligands epiregulin
and amphiregulin, phosphatase and tensin homolog loss or
mutations in NRAS and exon 20 PIK3CA may be useful to
further refine the responder population. However, the data
regarding their validity as predictive factors of responsiveness
are less consistent and the prospective studies necessary to
validate additional tests in selecting patients for anti-EGFR
monoclonal antibodies can take several years because of the
slow recruitment of patients harboring a rare mutation.
Up till now, clinical evidence all points towards the
identification of the KRAS mutation as the only evaluated and
reproducible predictive factor of resistance to anti-EGFR
antibodies. Indeed, future research will test clinical efficacy of
combined therapies simultaneously targeting the EGFR and
the RAS/RAF/MAPK signaling pathways for mCRC patients
in the context of mutational networks affecting the EGFR
pathway.
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